Effect of Ranolazine and Trimetazidine on Depression Paradigm in Male Swiss Albino Mice

Abstract

Introduction: Depression or Depressive Disorder is a common mental disorder that presents with depressed mood, loss of interest or pleasure, decreased energy, feelings of guilt or low self-worth, disturbed sleep or appetite, and poor concentration. Recent advances in neurobiological research have shown a growing body of evidence indicating inflammatory pathways have a role in the genesis of depression. Depression is caused by a complex combination of behavioural, neurotropic, immunological, neuroendocrine, and other physiological components. Excessive secretion of proinflammatory cytokines, such as interleukin-1 beta (IL-1), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-), causes sickness behavior, which has symptoms that are similar to those of depression, implying that cytokines have a role in depression. However, the current therapy available is with limited efficacy serious side effects. Objective of the study: 1. To study the effect of Ranolazine and Trimetazidine on Depression paradigm. 2. To compare Ranolazine and Trimetazidine with that of standard anti-depressant drug Fluoxetine